High-purity Recombinant HPV L1 Virus-like Particles

Creative Diagnostics provides top-quality Recombinant HPV L1 virus-like particles (VLPs) for vaccine development and immunological research and viral structure analysis. The HPV L1 VLPs we produce have a precise structure and uniform composition and stable architecture which matches the natural HPV capsid structure yet lacks infectious DNA and viral components to provide both safety and strong immune response. The VLPs received optimized recombinant expression and purification treatment which produced products that maintained high purity levels and uniform structure and displayed consistent antigenic properties. The native-like structure of these proteins makes them suitable for vaccine efficacy testing and antibody generation and neutralization assays.

We achieve innovative results through its structure refinement and particle assembly control system which produces consistent batch quality and better biological performance. Our Recombinant HPV L1 virus-like particles offer research-grade reliability and vaccine-grade performance because they have undergone complete analytical validation and can be produced at scale. Scientists can use these products to develop new HPV vaccines and diagnostic tests and immunotherapies because they provide reliable results for research and vaccine development.

Talk to our experts Available Products

Why Choose Creative Diagnostics' Recombinant HPV L1 Virus-like Particles Products?

The Recombinant HPV L1 Virus-like Particles (VLPs) from Creative Diagnostics serve as an excellent tool for HPV vaccine development and immunogenicity assessment and viral structure analysis. The production of these VLPs depends on recombinant expression systems which generate products that undergo strict quality checks to achieve high purity levels and uniform structure and consistent immunogenicity. The HPV L1 VLPs replicate the authentic HPV capsid structure by producing non-infectious DNA-free particles which generate stable and safe biological results for laboratory and animal research.

Recombinant HPV L1 VLPs serve as perfect materials for vaccine development and antibody production and diagnostic assay creation and immune response assessment. The self-assembly process of these proteins produces structures that resemble their natural state which makes them suitable for studying HPV antigen properties and immune responses and assembly processes. With excellent batch consistency and long-term stability, they support reliable and reproducible outcomes across diverse experimental settings. Our product advantages:

High Purity and Homogeneity

95% purity with uniform size and shape, confirmed by TEM and DLS.

Native-like Capsid Structure

L1 proteins self-assemble into 55 nm particles, preserving natural epitopes.

DNA-free and Non-infectious

Safe for in vitro and in vivo use; no viral DNA.

Strong Immunogenicity

Elicits robust neutralizing antibody responses.

Excellent Structural Stability

Maintains integrity under physiological conditions and moderate storage stress.

Batch-to-Batch Consistency

Reproducible assembly and antigenicity verified by standard assays.

Scalable Production

Compatible with insect, yeast, or mammalian expression systems.

Versatile Applications

Ideal for vaccines, diagnostics, neutralization assays, and virus–host studies.

Get a Quote

Case Study

Evaluation of Immunogenicity of Recombinant HPV L1 Virus-like Particles in Preclinical Vaccine Research

Objective:

The research investigates the ability of Recombinant HPV L1 VLPs to generate neutralizing antibodies and protective immune responses through preclinical mouse studies.

Methods:

• The manufacturing process for high-purity DNA-free HPV L1 VLPs needed baculovirus expression in insect cells followed by ultracentrifugation purification for VLP preparation.
• The study used BALB/c mice which received 10 μg of HPV L1 VLPs combined with aluminum hydroxide adjuvant through intramuscular injections on days 0, 14 and 28.
• The researchers collected serum samples at three time points which were days 14, 28 and 42. The researchers determined neutralizing antibody titers through a pseudovirion-based neutralization assay (PBNA). Structural integrity and epitope presentation were confirmed via TEM and ELISA.

Results:

• The second dose of HPV L1 VLPs led to strong neutralizing antibody responses in mice which became even more pronounced after the third dose.
• The TEM imaging results showed that VLPs kept their icosahedral shape intact during the complete research period.
• The ELISA results confirmed that the assay detected HPV L1 epitopes with both high sensitivity and specificity which proved that the antigens were correctly presented.
• The DNA-free VLPs showed no adverse effects or immune toxicity which proved their safety for use in living organisms.

Conclusion:

The recombinant HPV L1 VLPs produced strong and reliable and safe immune responses which proved them suitable for preclinical vaccine development and immunogenicity research. Their native-like capsid structure and batch-to-batch consistency ensure high-quality, scalable application for next-generation HPV vaccines.